Newbioideas

Therapeutic insights into PD-1 pathway blockade for Human cancer therapy: Agaricus blazei Murill (AbM) inhibits the expression of co-inhibitory receptor PD-1 on Antigen- Specific T-cells, increases the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes and augments anti-tumor activity via down-regulation of its target gene


AMOUNT: $ 150

A recent study from Division of Infectious Diseases, School of Medicine, Johns Hopkins University, Baltimore, MD 21218, United States shows that “TGF-β1-Mediated Smad3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer.” This study was published in the 28 September 2016 issue of Cancer Discovery (one of the best journals in Cancer Science with an impact factor of 19+) by Prof Andrea L. Cox, Park BV and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Therapeutic insights into PD-1 pathway blockade for Human cancer therapy: AbM (Agaricus blazei Murill) inhibits the expression of co-inhibitory receptor PD-1 on Antigen- Specific T-cells, increases the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes and augments anti-tumor activity via down-regulation of its target gene

Significance:

It has recently been shown that blocking PD-1 with antibodies one could make tumors shrink. This work, relating to Cancer immunotherapy, has been chosen as Science’s breakthrough of the year recently.

The study presented here suggests that AbM (Agaricus blazei Murill), by decreasing the expression of its target gene, it may suppress the expression of PD-1. Thereby, it may (1) increase the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes; (2) augment anti-tumor activity of the immune system; and (3) inhibit metastatic cancer progression.

Agaricus blazei Murill (AbM) suppresses the expression of PD-1 and augments anti-tumor immunity

Thus, pharmacological formulations encompassing “AbM (Agaricus blazei Murill) or an active compound isolated from Agaricus blazei Murill may be used to inhibit the progression of tumors.

Idea Proposed/Formulated by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Citation: Boominathan, L., Therapeutic insights into PD-1 pathway blockade for Human cancer therapy: Agaricus blazei Murill (AbM) inhibits the expression of co-inhibitory receptor PD-1 on Antigen- Specific T-cells, increases the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes and augments anti-tumor activity via down-regulation of its target gene, 7/october/2016, 11.22 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Undisclosed information: How Agaricus blazei Murill (AbM) suppresses the expression of PD-1 and augments anti-tumor immunity

satisfaction-guarantee

Results guaranteed if not refunded

Web: http://genomediscovery.org  or http://newbioideas.com

Courtesy: When you cite drop us a line at info@genomediscovery.org

# Research cooperation

REGISTER

   

Dr.Boominathan PhD

Dr Boominathan was the first one in the world to propose a p73/p63-dependent cancer suppressor pathway (Supported by a legally valid Invention disclosure document certified by an advocate-2002/3)

Add comment

Most popular